# Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

> **NCT03164967** · PHASE4 · COMPLETED · sponsor: **ADMA Biologics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Humoral Immune Response

## Interventions

- **BIOLOGICAL:** Bivigam

## Key facts

- **NCT ID:** NCT03164967
- **Lead sponsor:** ADMA Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-29
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164967, "Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03164967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*